Evidence map›Paper›PMID 39384226›Full record

ArticleBMJ open2024

Cohort profile: a nationwide study in Dutch

Maartje A C Schreurs, Muriel A Adank, Antoinette Hollestelle, Rosa de Groot, Denise J Stommel-Jenner, Christi J Van Asperen, Margreet G E M Ausems, Lieke P V Berger, Marinus J Blok, Klaartje van Engelen and 6 more

Abstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Maartje A C SchreursErasmus MC Cancer Centre, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1826-5344
Muriel A AdankNetherlands Cancer Institute, Amsterdam, The Netherlands.
Antoinette HollestelleErasmus Medical Center, Rotterdam, The Netherlands.
Rosa de GrootNetherlands Cancer Institute, Amsterdam, The Netherlands.
Denise J Stommel-JennerNetherlands Cancer Institute, Amsterdam, The Netherlands.
Christi J Van AsperenLeiden University Medical Center, Leiden, The Netherlands.
Margreet G E M AusemsMedical Genetics, UMC, Utrecht, The Netherlands.
Lieke P V BergerUMCG, Groningen, The Netherlands.
Marinus J BlokMaastricht UMC+, Maastricht, The Netherlands.
Klaartje van EngelenAmsterdam UMC Locatie AMC, Amsterdam, Netherlands.
Frans B L HogervorstNetherlands Cancer Institute, Amsterdam, The Netherlands.
Willemina Geurts-GieleErasmus MC, Rotterdam, The Netherlands.
Johan J P GilleAmsterdam UMC Locatie AMC, Amsterdam, Netherlands.
Marijke R WeversRadboudumc, Nijmegen, The Netherlands.
Marjanka K SchmidtEpidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Maartje J HooningErasmus MC, Rotterdam, The Netherlands m.hooning@erasmusmc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose

participantsWe invited all heterozygous and homozygous FINDINGS TO DATE: Mean age at study inclusion was 53 years. Linkage with the Netherlands Cancer Registry showed a younger age at diagnosis in homozygotes (mean age 41.7 years) and heterozygotes (47.9 years) than non-carriers (51.2 years). Furthermore, carriers were more often diagnosed with grade 2, oestrogen receptor-positive breast cancer and more often developed contralateral breast cancer than non-carriers. Most women consumed alcohol regularly and about half never smoked. FUTURE PLANS: Further data linkages with the Netherlands Cancer Registry will allow prospective follow-up and breast cancer risk assessment in unaffected women at the time of genetic testing, risk of contralateral breast cancer and survival in patients with breast cancer. Also, linkage with the nationwide network and registry of histopathology and cytopathology in The Netherlands (PALGA) allows us to retrieve tumour samples to study tumourigenesis.

Indexed as

Breast NeoplasmsCheckpoint Kinase 2Genetic Predisposition to DiseaseOvarian NeoplasmsAdultAgedCohort StudiesFemaleHeterozygoteHumansMiddle AgedNetherlandsPedigreeCheckpoint Kinase 2CHEK2 protein, humanBreast tumoursCancer geneticsEpidemiology

Identifiers

PMID39384226
PMCPMC11474769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.